MDMA is 3,4-methylenedioxymethamphetamine, a synthetic drug that carries both stimulant and mild hallucinogenic properties and reaches the street as ecstasy, molly, XTC, E, X, beans and Adams. The Drug Enforcement Administration's Diversion Control Division controls MDMA in Schedule I of the Controlled Substances Act and records that MDMA has no accepted medical use in the United States.
Two facts separate MDMA from the stimulants it is filed beside. MDMA is a ring-substituted derivative of phenethylamine whose pharmacological profile resembles the combined effects of amphetamine and mescaline. And a tablet sold as MDMA is frequently not MDMA at all: federal forensic laboratories record methamphetamine, 3,4-methylenedioxyamphetamine, ketamine, caffeine, amphetamine, cathinones, synthetic cannabinoids and opioids including fentanyl in tablets sold under that name.
The DEA's National Forensic Laboratory Information System has received nearly 269,000 reports of MDMA since 1997. Annual reports peaked in 2007 at over 24,000 and stood at over 5,600 in 2024.
What Is MDMA?
MDMA is a synthetic ring-substituted phenethylamine derivative with combined stimulant and mild hallucinogenic properties, controlled in Schedule I of the Controlled Substances Act. The DEA's drug and chemical evaluation summary for MDMA, published in February 2026, records the Schedule I status, the absence of any accepted medical use in the United States, and a pharmacological profile similar to the combined effects of amphetamine and mescaline.
Pharmacologists file MDMA separately from both parent classes because of a third effect set. de la Torre, Rafael and colleagues describe closeness to others, facilitation of interpersonal relationships and increased empathy as the distinctive entactogen properties of MDMA in their 2004 review "Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition" in Therapeutic Drug Monitoring. That combination places MDMA between the amphetamines and the classic psychedelic drugs rather than inside either group.
The following are the 7 street names the DEA records for MDMA in its February 2026 evaluation summary.
- Ecstasy
- Molly
- XTC
- E
- X
- Beans
- Adams
MDMA reaches users mainly as a tablet stamped with a logo, and also as capsules, powder and liquid. What the molecule does after swallowing is the same in every form.
How Does MDMA Affect the Brain?
MDMA releases serotonin, dopamine and norepinephrine by reversing the membrane transporters that normally reabsorb them and by emptying the vesicles that store them. Rudnick, Gary and Wall, Stephen C. established the serotonin half of that mechanism in their 1992 paper in the Proceedings of the National Academy of Sciences, showing that MDMA inhibits serotonin transport through direct interaction with the sodium-dependent serotonin transporter, stimulates serotonin efflux from plasma membrane vesicles, and dissipates the pH gradient that holds serotonin inside secretory vesicles.
Serotonin is not the only transmitter involved. de la Torre and colleagues describe MDMA as a potent releaser and reuptake inhibitor of presynaptic serotonin, dopamine and norepinephrine, which is why the drug produces stimulant effects alongside the emotional ones and why heart rate, blood pressure and pupil diameter rise together. The stimulant half of that neurotransmitter imbalance accounts for the cardiovascular load described further down this page.
Repeated use leaves a measurable mark on the serotonin system. McCann, Una D. and colleagues compared 23 abstinent MDMA users with 19 controls using two positron emission tomography ligands and found global serotonin transporter reductions in the MDMA group, with the loss tracking the intensity of past MDMA use and with exploratory analyses suggesting transporter measures recover over time. The DEA records the same finding from brain imaging in former MDMA users and states that clinical studies suggest MDMA increases the risk of long-term, perhaps permanent, problems with memory and learning.
How Long Does an MDMA High Last?
An MDMA high begins within 30 to 45 minutes of oral ingestion and lasts 4 to 6 hours, and longer durations have been reported, per the DEA's February 2026 evaluation summary. Vizeli, Patrick and Liechti, Matthias E. measured the same window under controlled conditions: pooling nine double-blind, placebo-controlled, crossover studies in 166 healthy subjects given 75 or 125 mg, they recorded a mean duration of subjective effects of 4.2 hours, with a range from 1.4 to 8.2 hours.
Two dosing habits stretch that window past the figures above, and the DEA names both. The table below sets the documented time course beside the practices that extend it.
| Measure | Value | Condition |
| Onset after oral ingestion | 30 to 45 minutes | Single oral dose |
| Duration of effects | 4 to 6 hours, longer durations reported | Single oral dose |
| Duration measured in controlled research | Mean 4.2 hours, range 1.4 to 8.2 hours | 166 healthy subjects, 75 or 125 mg, clinical setting |
| Stacking | Not characterized | Two or more tablets taken at once |
| Piggy-backing | Not characterized | A series of tablets taken across a short period |
A longer exposure is not the only cost of stacking. Every additional tablet adds to the thermal and cardiovascular load described next.
What Are the Physical Risks of MDMA Use?
The physical risks of MDMA use are hyperthermia, hyponatremia, acute kidney injury, cardiovascular strain and serotonin syndrome. High doses of MDMA interfere with the body's ability to regulate temperature, and the DEA records that the resulting sharp rise in body temperature leads to liver, kidney and cardiovascular failure and possibly death. Call 911 immediately for anyone who collapses, has a seizure, becomes confused or agitated with hot skin, or stops responding after taking MDMA, and call the Poison Help line at 1-800-222-1222 for guidance on any MDMA exposure that has not reached that point.
Water is the second mechanism, and it does its damage through the opposite pathway. Campbell, Gregory A. and Rosner, Mitchell H. describe serious hyponatremia and hyponatremia-associated deaths in their 2008 review "The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney" in the Clinical Journal of the American Society of Nephrology, and they attribute the condition to a combination of MDMA-driven arginine vasopressin secretion, MDMA-driven polydipsia, ready access to fluids, and the advice circulated at dance events to drink copiously. The same review records acute kidney injury after MDMA use, most commonly secondary to nontraumatic rhabdomyolysis and also reported alongside drug-induced liver failure and drug-induced vasculitis. Hall, Andrew P. and Henry, John A. describe hyperpyrexia with multi-organ failure as the established presentation of acute MDMA toxicity in their 2006 overview in the British Journal of Anaesthesia, written for the anaesthesia, intensive care and emergency clinicians who receive these patients.
Cardiovascular strain is measurable even under laboratory conditions with a known dose of pure MDMA. Vizeli and Liechti recorded systolic blood pressure above 160 mmHg in 33 percent of their 166 subjects, heart rate above 100 beats per minute in 29 percent, and body temperature above 38 degrees Celsius in 19 percent, with all three findings significantly more frequent after 125 mg than after 75 mg. de la Torre and colleagues name serotonin syndrome, presenting as increased muscle rigidity, hyperreflexia and hyperthermia, as characteristic of acute MDMA toxicity. Lesser physical effects the DEA records are tremors, involuntary teeth clenching, muscle cramps and blurred vision.
Is MDMA Addictive?
MDMA is habit-forming psychologically rather than physically, and the pattern people report is compulsive and escalating use rather than a physically dangerous withdrawal syndrome. Degenhardt, Louisa, Bruno, Raimondo and Topp, Libby reviewed the evidence in "Is ecstasy a drug of dependence?" in Drug and Alcohol Dependence in 2010 and concluded that the physical features of dependence play a more limited role for ecstasy than the psychological ones.
Three findings in that review carry the answer. Tolerance is apparent, so a given quantity produces less effect over time. Withdrawal is self-reported, but the reports do not clearly separate the sub-acute after-effects of intoxication from the neuroadaptive process a true withdrawal syndrome requires. And the structure of ecstasy dependence differs from the structure seen with alcohol, methamphetamine and opioids, resolving into two factors the authors describe as compulsive use and escalating use. Degenhardt and colleagues also record that a minority of people who use ecstasy become concerned about that use and seek treatment, which is the clinical population this page is written for.
What Is Actually in Street MDMA?
Tablets sold as MDMA frequently contain synthetic cathinones, other stimulants or opioids instead of MDMA, or alongside it. Palamar, Joseph J. and colleagues surveyed 679 nightclub and festival-attending young adults aged 18 to 25 in New York City in 2015 and analysed hair samples from the 48 participants who reported lifetime ecstasy, MDMA or Molly use. Half of those samples contained MDMA. Butylone appeared in 47.9 percent and methylone in 10.4 percent.
The finding that matters most concerns people who believed they had never taken these substances. Among participants who reported no lifetime use of bath salts, stimulant novel psychoactive substances or unknown pills and powders, 41.2 percent tested positive for butylone, methylone, alpha-PVP, 5/6-APB or 4-FA. The exposure was therefore unintentional, and the study population sat in the same New York City nightlife scene that draws people across the Hudson from Bergen County.
Federal forensic laboratories find a wider list still. The table below groups what the DEA records inside tablets sold as ecstasy.
| Class | Substances recorded in tablets sold as MDMA | Why the class changes the risk |
| Stimulants | Methamphetamine, amphetamine, caffeine | Adds cardiovascular and thermal load to a drug that already raises heart rate and temperature |
| Synthetic cathinones | Butylone, methylone, alpha-PVP | Sold as bath salts, and detected in hair samples of people reporting no such use |
| Dissociatives and related phenethylamines | Ketamine, 3,4-methylenedioxyamphetamine | Produces effects the person did not choose and cannot dose for |
| Synthetic cannabinoids | Unspecified in the DEA summary | Carries a toxicity profile unrelated to MDMA |
| Opioids | Fentanyl and fentanyl analogues | Introduces respiratory depression to a person with no opioid tolerance |
The opioid row changes what an emergency looks like. A person who took what they believed was ecstasy and then stops breathing is showing an opioid overdose, and naloxone reverses opioid overdose whether or not anyone at the scene knew an opioid was involved. The stimulant row is why a tablet can produce the sweating, jaw tension and racing pulse of methamphetamine use rather than the effects the person expected.
What Are the Signs of MDMA Misuse?
The signs of MDMA misuse are physical during use and psychological in the days that follow. The DEA records tremors, involuntary teeth clenching, muscle cramps and blurred vision as physical effects, alongside the raised heart rate, blood pressure and motor activity that accompany any stimulant. Confusion, anxiety, depression and paranoia follow, and the DEA states those effects last weeks after ingestion.
The following are the 6 behavioural indicators recorded in the DEA evaluation summary and in the DSM-IV criteria Cottler, Linda B. and colleagues applied specifically to ecstasy in Human Psychopharmacology in 2001.
- Stacking two or more tablets at once
- Piggy-backing a series of tablets across a short period
- Combining MDMA with lysergic acid diethylamide, a practice named candy flipping
- Continuing to use despite knowing the physical or psychological harm, reported by 63 percent of the 52 people who used ecstasy in Cottler's sample
- Reporting withdrawal-like symptoms, reported by 59 percent of that group
- Needing more MDMA for the same effect, reported by 35 percent of that group
Cottler and colleagues drew that sample from 173 adolescents and young adults recruited through a substance use program, high school advertisements, college dormitory flyers and the internet, so the percentages describe a help-seeking and nightlife-connected group rather than the general population. The mid-week pattern the psychological signs follow is documented in its own right.
What Happens During an MDMA Comedown?
An MDMA comedown arrives several days after use as low mood and impaired attention, not on the following morning. Curran, H. Valerie and Travill, Roger A. compared 12 people who took MDMA with 12 who drank only alcohol on the same night, reassessed both groups the next day and again mid-week, and published the result in Addiction in 1997 under the title "Mood and cognitive effects of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low".
The MDMA group rated elevated mood on the night of use and significantly low mood on day 5, at which point some participants scored within the range for clinical depression. The same group showed significant impairment on an attention and working-memory task compared with the alcohol group, whose mood dipped on day 2 and recovered. Curran and Travill discuss temporary depletion of serotonin, serotonergic neurotoxicity and psychological factors as the candidate mechanisms. The delay is what makes the pattern easy to miss: a person who feels fine on Sunday and flat on Wednesday rarely connects the two, and the DEA's finding that confusion, anxiety, depression and paranoia last weeks after ingestion describes the longer version of the same curve.
How Common Is MDMA Use?
MDMA use concentrates among adolescents and young adults, and reaches them at music festivals and nightclubs and, more recently, on college campuses, per the DEA's February 2026 evaluation summary.
Forensic volume tracks that population across three decades. The DEA's National Forensic Laboratory Information System has received nearly 269,000 reports of MDMA since 1997, recorded its peak in 2007 at over 24,000 reports in that year alone, and received over 5,600 reports in 2024. Those counts measure drug items analysed by participating federal, state and local laboratories rather than the number of people using MDMA.
Is MDMA Legal in the United States?
MDMA is illegal to manufacture, distribute or possess in the United States and is controlled in Schedule I of the Controlled Substances Act. Schedule I is the classification reserved for substances with no currently accepted medical use and a high potential for abuse, and the DEA states plainly that MDMA has no accepted medical use in the United States.
MDMA remains investigational. Vizeli and Liechti describe MDMA as under investigation in MDMA-assisted psychotherapy in their 2017 paper in the Journal of Psychopharmacology, and an investigational designation is a research status rather than a change in legal control, an approval, or a route to availability. A person facing a possession charge alongside a substance use problem is dealing with two systems at once, and treatment addresses one of them directly.
How Is Problematic MDMA Use Treated?
Problematic MDMA use is treated with psychiatric assessment of the mood and cognitive symptoms that outlast the drug, followed by behavioural therapy for the use pattern itself. No medication is approved to treat MDMA use disorder, so the clinical work is diagnostic and psychotherapeutic.
The psychiatric half is what separates MDMA cases from other stimulant cases. Depression, anxiety, paranoia and attention problems persist for weeks after use, per the DEA, and the serotonin transporter reductions McCann and colleagues measured recover over time rather than immediately. A person in early recovery therefore feels flat during exactly the period when motivation matters most, and that flatness is a treatable symptom rather than a permanent state. Valley Spring Recovery Center evaluates co-occurring psychiatric and substance use conditions together through dual diagnosis treatment in Norwood, New Jersey, and treats adults 18 and older. The clinical detail on levels of care, therapies and admission sits on the page covering MDMA addiction treatment in Bergen County. Admissions staff at (855) 924-5320 complete a free, confidential pre-assessment at any hour.
What Are the Most Common Questions About MDMA?
The 6 questions below cover duration, purity, legality and comedown facts people search most about MDMA.
What Does MDMA Stand For?
MDMA stands for 3,4-methylenedioxymethamphetamine. The molecule is a ring-substituted derivative of phenethylamine, and the DEA records its pharmacological profile as similar to the combined effects of amphetamine and mescaline.
How Long Does MDMA Last?
Oral MDMA acts within 30 to 45 minutes and lasts 4 to 6 hours, with longer durations reported, per the DEA. Vizeli and Liechti measured a mean of 4.2 hours across 166 healthy subjects, ranging from 1.4 to 8.2 hours.
Is Ecstasy the Same Thing as Molly?
Ecstasy and Molly are both street names for MDMA, and the DEA lists them together with XTC, E, X, Beans and Adams. Neither name guarantees the contents: half the hair samples from self-reported users in one New York City study contained MDMA.
Can MDMA Kill You?
Yes. High doses interfere with temperature regulation, and the resulting hyperthermia leads to liver, kidney and cardiovascular failure and possibly death, per the DEA. Call 911 for a collapse, a seizure or unresponsiveness, and Poison Help at 1-800-222-1222 otherwise.
Why Do I Feel Depressed Days After Taking MDMA?
Curran and Travill found low mood on day 5 after weekend MDMA use, with some participants scoring within the clinical depression range, and named temporary serotonin depletion among the candidate mechanisms. The DEA records depression lasting weeks after ingestion.
Does MDMA Cause Withdrawal?
No medically dangerous withdrawal syndrome is established for MDMA. Degenhardt, Bruno and Topp found withdrawal self-reported but not clearly distinguishable from the sub-acute after-effects of intoxication, while tolerance was apparent.
Most health insurance plans cover substance use disorder treatment.